Abstract
Pompe disease, a rare, autosomal, recessive, inherited, lysosomal storage disorder, is caused by mutations in the acid α-glucosidase (GAA) gene leading to a deficiency of the lysosomal GAA enzyme. Some GAA mutations eliminate all enzymatic activities, causing severe infantile Pompe disease; others allow residual GAA activity and lead to middle adulthood forms. Here, we report a cohort of 12 patients, belonging to 11 unrelated families, with infantile Pompe disease. The mutational analysis of GAA gene revealed a novel c.1494G > A (p.Trp498X) mutation in one patient and three known mutatio,ns including the c.1497G > A (p.Trp499X) mutation, in two patients, the c.1927G > A (p.Gly643Arg) mutation in one patient and the common c.236_246del (p.Pro79ArgfsX13) mutation in eight patients. The high prevalence of c.236_246del mutation in our cohort (58%) was supported by the existence of a common founder ancestor that was confirmed by its segregation of similar SNPs haplotype, including four intragenic SNPs of GAA gene. In addition, a 3D structure model and a docking were generated for the mutant p.Gly643Arg using the crystal structure of human GAA as template and the 4-methylumbelliferyl-α-D-glucopyranoside as substrate. The results showed that the arginine at position 643 caused electrostatic changes in neighboring regions, leading to the repulsion between the amino acids located in the catalytic cavity of the GAA enzyme, thus restricting access to its substrate. These structural defects could cause the impairment of the transport and maturation previously reported for p.Gly643Arg mutation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
ACMG Work Group on Management of Pompe Disease, Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, Case L, Crowley JF, Downs S, Howell RR, Kravitz RM, Mackey J, Marsden D, Martins AM, Millington DS, Nicolino M, O’Grady G, Patterson MC, Rapoport DM, Slonim A, Spencer CT, Tifft CJ, Watson MS (2006) Pompe disease diagnosis and management guideline. Genet Med Off J Am Coll Med Genet 8:267–288. https://doi.org/10.1097/01.gim.0000218152.87434.f3
Becker JA, Vlach J, Raben N, Nagaraju K, Adams EM, Hermans MM, Reuser AJ, Brooks SS, Tifft CJ, Hirschhorn R, Huie ML, Nicolino M, Plotz PH (1998) The African origin of the common mutation in African American patients with glycogen-storage disease type II. Am J Hum Genet 62:991–994. https://doi.org/10.1086/301788
Fereidoonnezhad M, Mostoufi A, Eskandari M, Zali S, Aliyan F (2018) Multitarget drug design, molecular docking and PLIF studies of novel Tacrine−Coumarin hybrids for the treatment of Alzheimer’s disease. Iran J Pharm Res IJPR 17:1217–1228
Gort L, Coll MJ, Chabás A (2007) Glycogen storage disease type II in Spanish patients: high frequency of c.1076-1G>C mutation. Mol Genet Metab 92:183–187. https://doi.org/10.1016/j.ymgme.2007.05.011
Hagemans MLC, Winkel LPF, Hop WCJ, Reuser AJJ, Van Doorn PA, Van der Ploeg AT (2005) Disease severity in children and adults with Pompe disease related to age and disease duration. Neurology 64:2139–2141. https://doi.org/10.1212/01.WNL.0000165979.46537.56
Hermans MM, de Graaff E, Kroos MA, Wisselaar HA, Willemsen R, Oostra BA, Reuser AJ (1993a) The conservative substitution Asp-645-->Glu in lysosomal alpha-glucosidase affects transport and phosphorylation of the enzyme in an adult patient with glycogen-storage disease type II. Biochem J 289(Pt 3):687–693. https://doi.org/10.1042/bj2890687
Hermans MM, Kroos MA, de Graaff E, Oostra BA, Reuser AJ (1993b) Two mutations affecting the transport and maturation of lysosomal alpha-glucosidase in an adult case of glycogen storage disease type II. Hum Mutat 2:268–273. https://doi.org/10.1002/humu.1380020406
Hermans MM, Kroos MA, Smeitink JA, van der Ploeg AT, Kleijer WJ, Reuser AJ (1998) Glycogen storage disease type II: genetic and biochemical analysis of novel mutations in infantile patients from Turkish ancestry. Hum Mutat 11:209–215. https://doi.org/10.1002/(SICI)1098-1004(1998)11:3<209::AID-HUMU5>3.0.CO;2-C
Hermans MM, Wisselaar HA, Kroos MA, Oostra BA, Reuser AJ (1993c) Human lysosomal alpha-glucosidase: functional characterization of the glycosylation sites. Biochem J 289(Pt 3):681–686. https://doi.org/10.1042/bj2890681
Hirschhorn R, Huie ML (1999) Frequency of mutations for glycogen storage disease type II in different populations: the delta525T and deltaexon 18 mutations are not generally “common” in white populations. J Med Genet 36:85–86
Huie ML, Chen AS, Tsujino S, Shanske S, DiMauro S, Engel AG, Hirschhorn R (1994) Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular identification of an IVS1 (−13T-->G) mutation in a majority of patients and a novel IVS10 (+1GT-->CT) mutation. Hum Mol Genet 3:2231–2236. https://doi.org/10.1093/hmg/3.12.2231
Kornfeld S (1986) Trafficking of lysosomal enzymes in normal and disease states. J Clin Invest 77:1–6. https://doi.org/10.1172/JCI112262
Kroos M, Hoogeveen-Westerveld M, van der Ploeg A, Reuser AJJ (2012) The genotype-phenotype correlation in Pompe disease. Am J Med Genet C Semin Med Genet 160C:59–68. https://doi.org/10.1002/ajmg.c.31318
Laforêt P, Nicolino M, Eymard PB, Puech JP, Caillaud C, Poenaru L, Fardeau M (2000) Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation. Neurology 55:1122–1128. https://doi.org/10.1212/wnl.55.8.1122
Lewin HA, Stewart-Haynes JA (1992) A simple method for DNA extraction from leukocytes for use in PCR. BioTechniques 13:522–524
Martiniuk F, Bodkin M, Tzall S, Hirschhorn R (1991) Isolation and partial characterization of the structural gene for human acid alpha glucosidase. DNA Cell Biol 10:283–292. https://doi.org/10.1089/dna.1991.10.283
Moreland RJ, Jin X, Zhang XK, Decker RW, Albee KL, Lee KL, Cauthron RD, Brewer K, Edmunds T, Canfield WM (2005) Lysosomal acid alpha-glucosidase consists of four different peptides processed from a single chain precursor. J Biol Chem 280:6780–6791. https://doi.org/10.1074/jbc.M404008200
Pittis MG, Filocamo M (2007) Molecular genetics of late onset glycogen storage disease II in Italy. Acta Myol Myopathies Cardiomyopathies Off J Mediterr Soc Myol 26:67–71
Raben N, Plotz P, Byrne BJ (2002) Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease). Curr Mol Med 2:145–166. https://doi.org/10.2174/1566524024605789
Reuser AJ, Kroos M, Oude Elferink RP, Tager JM (1985) Defects in synthesis, phosphorylation, and maturation of acid alpha-glucosidase in glycogenosis type II. J Biol Chem 260:8336–8341
Shieh JJ, Lin CY (1998) Frequent mutation in Chinese patients with infantile type of GSD II in Taiwan: evidence for a founder effect. Hum Mutat 11:306–312. https://doi.org/10.1002/(SICI)1098-1004(1998)11:4<306::AID-HUMU8>3.0.CO;2-S
Sugawara K, Saito S, Sekijima M, Ohno K, Tajima Y, Kroos MA, Reuser AJJ, Sakuraba H (2009) Structural modeling of mutant alpha-glucosidases resulting in a processing/transport defect in Pompe disease. J Hum Genet 54:324–330. https://doi.org/10.1038/jhg.2009.32
Turaça LT, de Faria DOS, Kyosen SO, Teixeira VD, Motta FL, Pessoa JG, Rodrigues E, Silva M, de Almeida SS, D’Almeida V, Munoz Rojas MV, Martins AM, Pesquero JB (2015) Novel GAA mutations in patients with Pompe disease. Gene 561:124–131. https://doi.org/10.1016/j.gene.2015.02.023
Van den Hout JMP, Kamphoven JHJ, Winkel LPF, Arts WFM, De Klerk JBC, Loonen MCB, Vulto AG, Cromme-Dijkhuis A, Weisglas-Kuperus N, Hop W, Van Hirtum H, Van Diggelen OP, Boer M, Kroos MA, Van Doorn PA, Van der Voort E, Sibbles B, Van Corven EJJM, Brakenhoff JPJ, Van Hove J, Smeitink JAM, de Jong G, Reuser AJJ, Van der Ploeg AT (2004) Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 113:e448–e457. https://doi.org/10.1542/peds.113.5.e448
Van der Kraan M, Kroos MA, Joosse M, Bijvoet AG, Verbeet MP, Kleijer WJ, Reuser AJ (1994) Deletion of exon 18 is a frequent mutation in glycogen storage disease type II. Biochem Biophys Res Commun 203:1535–1541. https://doi.org/10.1006/bbrc.1994.2360
Wisselaar HA, Kroos MA, Hermans MM, van Beeumen J, Reuser AJ (1993) Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation. J Biol Chem 268:2223–2231
Acknowledgments
We thank Professor Nabil Miled (Laboratory of Biochemistry and Enzymatic Engineering of Lipases, ENIS) for sharing his expertise in modeling and docking, as well as for providing us with the PMV, AutoDock Vina, Discovery Studio visualizer and Pymol software. This work was supported by The Ministry of Higher Education and Scientific Research in Tunisia.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of Interest
The authors declare that they have no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Alila-Fersi, O., Aloulou, H., Werteni, I. et al. Mutations in GAA Gene in Tunisian Families with Infantile Onset Pompe Disease: Novel Mutation and Structural Modeling Investigations. J Mol Neurosci 70, 1100–1109 (2020). https://doi.org/10.1007/s12031-020-01516-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12031-020-01516-9